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HEPARANASE activity  is  correlated  with  the metastatic
potential of several cancer cells and is a key enzyme
in the breakdown of tissue barriers. It is also involved
in  the  regulation  of  growth  factor  and  cytokine
activity.  However,  little  is  known about  the  factors
that  induce  heparanase  in  cancer  cells.  We  investi-
gated  the  effect  of  three  growth  factors,  platelet-
derived  growth  factor  (PDGF),  hepatocyte  growth
factor  (HGF)  and  basic  fibroblast  growth  factor
(bFGF),  on  heparanase  mRNA  induction  in  lung
cancer  cells  in  vitro.  In  addition,  we examined  the
effect  of  erythromycin  (EM)  and  clarithromycin
(CAM), which are 14-membered ring macrolide anti-
biotics  that act as biological response modifiers, on
the  expression  of  heparanase  mRNA  induced  by
growth factors.
PDGF,  HGF  and  bFGF  stimulated  cell  migration
activity and enhanced the expression of heparanase
mRNA in the human lung adenocarcinoma cell line
A549. Via different mechanisms, EM and CAM mod-
ulate  the  induction  by  these  factors  of  heparanase
mRNA expression on A549 cells. EM also significantly
suppressed A549 cell migration induced by PDGF and
HGF,  and  CAM  significantly  suppressed  A549  cell
migration induced by bFGF.
The results suggest that the growth factors PDGF,
HGF and bFGF are important inducers of heparanase
in  potentially  invasive  and  metastatic  cancer  cells.
The suppressive effect of heparanase mRNA expres-
sion by EM and CAM may have interesting therapeutic
applications in the prevention of metastasis.
Key  words:  Heparanase,  Lung  cancer,  Growth  factor,
Erythromycin, Clarithromycin
Introduction
Cancer cell  migration  through  the  basement  mem-
branes  and degradation of  extracellular matrix  pro-
teins play an essential role in the various biological
and  pathological  processes  in  tumor  invasion  and
metastasis.
Histological  specimens  from  lung  cancers  have
documented that central fibrosis and active fibroblast
proliferation  are  among  the  most  important  prog-
nostic  factors  for  small  bronchioalveolar  carci-
noma.1,2 These same studies emphasized the impor-
tance  of  cancer  cell-fibroblast  interactions  in  the
process  of  metastasis.  These  interactions  regulate
growth  factor  and  matrix  metalloproteinase (MMP)
production  in  cancer  cells,  which  leads  to  the
continuation of cell migration.3–5
Heparan sulfate proteoglycans (HSPGs) are prima-
rily  the  chief  component  of  extracellular  matrix
protein  and  are  also  important  structures  in  base-
ment membranes. HSPGs are thought to be involved
in  cell  adhesion, migration, proliferation and angio-
genesis.6,7 Various  classes  of  enzymes  have  been
reported  to  play  a  role  in  the  metastatic  process
including  serine  and  cysteine  protease,  MMP  and
heparanase.8–11
Heparanase is an endo-b -D-glucuronidase  capable
of heparan sulfate cleavage, and is reportedly found
mainly  in  platelets,  placental  trophoblasts,  leuko-
cytes,  melanomas  and  hepatomas.12–15 Recently,
overexpression  of  heparanase  in  tumor  cells  was
shown  to  confer  a  high  metastatic  potential  in
experimental mice.16,17 These reports suggested that
heparanase  may  be  the  key  enzyme  in  the  break-
down of tissue barriers and may be involved in the
regulation  of  growth  factors  and  cytokine  activity.
However,  less  is  known  about  the  factors  that
induce heparanase mRNA expression on cancer cells
during invasion and metastasis.
Erythromycin (EM) and clarithromycin (CAM) are
14-membered ring macrolide antibiotics that report-
edly suppress neutrophil accumulation and effectively
treat chronic lower respiratory tract disease.18 Recent
studies have suggested that compounds of this class
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thromycin,  another  14-membered  ring  macrolide
antibiotic,  has  been  shown  to  have  an  inhibitory
effect on tumor angiogenesis.19 These findings  sug-
gest that EM and CAM may have anti-metastatic effects
on the host-defense system.20.21
Consequently, we investigated the effects of growth
factors on the induction of heparanase mRNA expres-
sion on lung  cancer cells in vitro. Additionally, we
examined the effect of EM and CAM on the expres-
sion of heparanase mRNA induced by growth factors
in vitro.
Materials and methods
Materials
Recombinant  human  platelet-derived  growth  factor
(PDGF)-BB, hepatocyte growth factor (HGF) and basic
fibroblast growth factor (bFGF) were purchased from
Genzyme (USA). Heparin (porcine), for which activity
was 1 ´ 103 U/ml, was purchased from Novo Nordlisk
(Denmark). EM  was provided by  Dainavot Pharma-
ceutical Co., Ltd (Japan), and CAM was provided by
Dainihon  Pharmaceutical  Co.,  Ltd  (Japan).  Tissue
culture plates were obtained from Sumitomo Bakelite
(Japan)  and  Transwell  culture  dishes  were  from
Corning Coster (USA). The Matrigel invasion chamber
was supplied by Falcon (USA).
Cell culture
Human lung  fibroblasts-1, obtained from Riken Cell
Bank (Japan), were cultured in a cell culture flask in
modified Ham’s F12 (Sigma) supplemented with 10%
fetal calf serum (FCS) at 37°C in an atmosphere of 5%
CO2 without  antibiotics.  A549  cells  (human  lung
adenocarcinoma),  obtained  from  Japanese  Cancer
Research Resources Bank (Japan), were cultured in a
cell culture flask in RPMI1640 (Sigma) supplemented
with 10% FCS at 37°C in an atmosphere of 5% CO2,
95%  air  without  antibiotics.  The  cells  grown  to
confluence  were  removed  from  the  culture  flask,
plated at 1.0 ´ 105 cells in a 35mm petri dish and
incubated with PDGF (2 m g/ml), HGF (4 m g/ml), bFGF
(2 m g/ml) and heparin (10U/ml) without serum and
antibiotics for 6h. Cells were removed from the plates
with phosphate-buffered saline and ethylenediamine-
tetraacetic acid, replaced and suspended in a micro
test tube with 1ml of F12 or RPMI 1640 media. Cell
counts and viability were determined by Trypan blue
exclusion (GIBCO) and counted by a hemocytometer.
To investigate the effect of EM and CAM, we cultured
A549  cells  and  fibroblasts  with  EM  (10m g/ml)  and
CAM (10 m g/ml) for 30min prior to the addition of
the growth factors.
Cell migration assay
Cell  migration  induced  by  PDGF  (2ng/ml),  HGF
(4ng/ml), bFGF (2ng/ml) and heparin (10U/ml) were
measured  using  the  modified  Boyden  chamber  as
described previously.14 The test compounds diluted
with Ham’s F12 medium were placed in wells in the
upper chamber. The wells were covered with Matri-
gel-coated  polycarbonate  filters.  Human  lung  fibro-
blasts (5 ´ 104 cells) and medium were then added to
the  wells  in  the  upper  chamber.  Using  the  same
method as already described, A549 cells (5 ´ 104 cells)
and  medium  were  then  added to  the  wells  in  the
upper chamber. PDGF, HGF and bFGF were added to
the  wells  in  the  upper  chamber  for  the  migration
assay.  Heparin  (10U/ml)  was  used  as  the  anti-
heparanase compound. After a 6h incubation at 37°C
in 5% CO2, the filters were removed and cells were
fixed and stained using Diff-Quik stain (International
Reagents Co., Japan). Cell migration was determined
by counting the number of cells/microscopic field on
the lower surface.
Reverse transcription polymerase chain
reaction amplification
Total RNA was extracted from fibroblasts and A549
cells using the acid–guanidinium–phenol method, as
per the manufacturer’s instructions (AmpliTaq Gold;
Roch Molecular System, Inc., USA). First-strand cDNA
was  prepared  from  0.3m g  of  total RNA  in  a  20 m l
reaction volume that consisted of 50 mM of Tris (pH
8.3),  75 mM  of  KCl,  3 mM  of  MgCl2,10 mM  of
dithiothreitol,  0.5 mM  of  dNTPs,  120U  of  RNAse
inhibitor, and 16U of reverse transcriptase (RT).
Oligonucleotide primers for polymerase chain reac-
tion (PCR) amplification of heparanase were designed
according  to  published  DNA  sequences  for  hepar-
anase.17 The following primers were used:
HPU-380Y, 59 -CGATCCCAAGAAGGAATCAA-39 ;
HPL-812Y, 59 -TAACTGCGACCCATTGATGA-39 .
Amplification  was  performed  in  a  final  volume  of
100 m l with 15 mM of Tris (pH 8.0), 50 mM of KCl,
1.5 mM of MgCl2, 0.2 mM of dNTPs, 1.0 m mol of each
primer and 2.5U of Taq polymerase. After a “hot-start”
(95°C,  10min),  each  cycle  consisted  of  40sec  of
denaturation at 94°C, 1min of annealing at 58°C, and
2min of elongation at 72°C. Reactions were run for
35 cycles.
Data analysis
Results are expressed as mean ± the standard error of
the mean (SEM). A comparison of the effect of A549
cell migration within experiments was performed by
analysis of variance. Statistical significance was estab-
lished at the p < 0.05 level.
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Cell migration assay
PDGF, HGF and bFGF induced significantly increased
migration in human lung fibroblasts and A549 cells,
whereas heparin significantly inhibited cell migration
in  both  (p <  0.05;  Fig.  1).  EM  and  CAM  did  not
suppress fibroblast migration induced by PDGF, HGF
and bFGF (data not shown).
However,  EM  significantly  suppressed  A549  cell
migration  induced  by  PDGF  and  HGF,  and  CAM
significantly suppressed A549 cell migration induced
by bFGF (p < 0.05; Fig. 2).
Effect of growth factors on heparanase mRNA
expression in human lung fibroblast
Fibroblasts when cultured with serum-free  medium
revealed weakly expressed heparanase mRNA, which
was not increased by PDGF, HGF or bFGF. Heparin
had  no  inhibitory  effects  on  heparanase  mRNA
expression (Fig. 3).
Effect of growth factors on heparanase mRNA
expression in A549 cells
A549 cells did not express heparanase mRNA when
cultured with serum-free medium. However, growth
factors  such  as  PDGF,  HGF  and  bFGF  did  induce
heparanase  mRNA  expression.  Heparin  had  no
inhibitory  effects  on  heparanase  mRNA  expression
(Fig. 3).
Effect of EM and CAM on heparanase mRNA
induced by growth factors in A549 cells
EM suppressed the expression of heparanase mRNA
induced  by  PDGF  and  HGF,  but  did  not  suppress
heparanase mRNA expression induced by bFGF (Figs.
4 and 5).
In contrast, CAM suppressed expression of hepar-
anase mRNA induced by bFGF, but not that induced
by PDGF or HGF (Fig. 6).
Discussion
In  the  present  study,  we  demonstrated that  PDGF,
HGF and bFGF stimulated cell migration of the human
lung cancer cell line. More importantly, these growth
factors induced heparanase mRNA expression on the
lung cancer cell line in vitro.
EM and CAM expression of heparanuse mRNA
Mediators of Inflammation · Vol 10 · 2001 261
FIG. 1. Cell migration assay in response to PDGF, HGF and
bFGF. Bar graph representing the effect of stimulus alone (h )
and stimulus in the presence of heparin (j ). PDGF, HGF and
bFGF  induced  significantly  increased  migration  in  both
fibroblasts and lung cancer cells (A549). Heparin inhibited
both fibroblast and lung cancer cell migration induced by
PDGF, HGF and bFGF. The vertical line represents the SEM of
quadruplicate  analyses.  *  p <  0.05  when  compared  with
controls (no factors).
FIG. 2. Bar graph representing the effect of EM and CAM on
A549 cell migration induced by PDGF, HGF and bFGF. The
vertical line represents the SEM of quadruplicate analyses. *
p <  0.05  when  compared  with  individual  growth  factor
treatment only.M. Sasaki et al.
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.Tumor cell migration plays an important role in the
process  of  metastasis.22 Growth  factors,  including
PDGF, HGF and bFGF, and extracellular matrix compo-
nents are known requirements  for cell migration.23
Furthermore,  the  existence  of  PDGF  and  PDGF
receptors is reported to be a prognostic indicator in
lung  cancers.24 Produced  by  several  tumor  cells,
fibroblasts  and  endothelial  cells,  bFGF  has  been
implicated  in  the  induction  of  the  angiogenic  and
stromal responses.25 Also, it is now recognized that
HGF  has multiple  effects, such as mitogenic, moto-
genic, and angiogenic effects.26 These growth factors
are  produced  by  tumor  and  tumor-associated  host
tissue such as fibroblasts and mesenchymal cells.27,28
To determine whether growth factors play a biolog-
ical role in the migration of human lung fibroblasts
and  cancer  cells,  we  used  a  cell  migration  assay
employing  the  modified  Boyden  chamber  method.
The cells migrated in a dose-dependent manner (data
not  shown),  suggesting  that  PDGF,  HGF  and  bFGF
influence A549  cells and  fibroblast  migration. Addi-
tionally,  PDGF,  HGF  and  bFGF  induced  heparanase
mRNA  expression  on A549  cells  but  not  on  fibro-
blasts. Our previous study demonstrated that MMP-1
and MMP-9 were strongly positive in the cytoplasma
of  fibroblasts,  and  they  retained  MMP-1  and  MMP-
2/MMP-9  activity when  stimulated by  PDGF.6 More
recent studies have demonstrated that heparin  and
MMP-2 correlate with the proteolytic cleavage sites of
fibronectin and anti-adhesive effects.29 These results
suggest that fibroblasts and tumor cells may employ
different  mechanisms  of  cell  migration.  Our  data
supports the fact that heparanase is inducible in A549
cells by growth factors that also increase migration of
these cells in vitro.
Our results provide proof that growth factors do
indeed  play  an  important  role  in  the  induction  of
heparanase mRNA expression in potentially invasive
and  metastatic  cancer  cells.  Inhibition  of  these
growth factors, which usually cause increased expres-
sion of heparanase, may have a net effect of inhibiting
tumor metastasis.
Our  data revealed  that  heparin  inhibited  growth
factor-induced  A549  cell  migration,  which  is  sup-
ported  by  the  fact  that  heparin  is  one  of  the
heparanase-inhibitory molecules.30–33
Our  cell  migration  assay  demonstrated  that  EM
inhibited A549 cell migration induced by PDGF and
HGF,  whereas  CAM  inhibited  A549  cell  migration
induced by bFGF. We also found that EM and CAM
modulated  heparanase  mRNA  expression  on  A549
cells induced by growth factors, but in a differential
manner. Recent studies have shown that EM enhan-
ces  natural  killer  cell  activity  and  increases  the
survival  times  of  tumor-bearing  mice.34 It  has  also
been  found  that  CAM  increases  natural  killer  cell
activity and CD8 T-cell cytotoxicity to reduce tumor
growth  in  the  murine  lung  cancer  model.35 We
report  here  for  the  first  time  that  EM  and  CAM
suppress  heparanase  mRNA  expression  and  thus
inhibit tumor cell migration. However, further study
is required to understand the different mechanisms
that occur for EM suppression of PDGF-induced and
HGF-induced heparanase mRNA expression, and for
the CAM suppression of bFGF-induced expression of
heparanase mRNA.
In conclusion, our results  provide clear evidence
that PDGF, HGF and bFGF growth factors are impor-
tant inducers of heparanase in potentially invasive and
metastatic cancer cells. EM and CAM produce inhibi-
tory effects on growth factors that induce heparanase
mRNA expression and may, therefore, have possible
therapeutic applications in the future.
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